OVV-Beclin1

OVV-Beclin1 is an **oncolytic vaccinia virus** engineered to express the **Beclin-1 gene**, a critical regulator of autophagy. The drug is designed to induce **excessive autophagy** in cancer cells, leading to cell death through an autophagic mechanism rather than apoptosis. Mechanistically, OVV-Beclin1 infects tumor cells, upregulates Beclin-1, and triggers the autophagy signaling cascade. This process results in the formation of autophagosomes involving LC3B and other autophagy proteins, culminating in tumor cell death. OVV-Beclin1 has demonstrated notable preclinical efficacy against **non-Hodgkin lymphoma (NHL)**, **leukemia**, and **multiple myeloma (MM)**, and has been shown to enhance the sensitivity of tumor cells to standard chemotherapeutics like R-CHOP. The vector can spread through tumor tissue, further intensifying its antitumor effect through both direct oncolytic activity and autophagy induction. The drug also upregulates SIRT-1, leading to increased cytoplasmic LC3, contributing to autophagy. Its primary indication is for various **blood cancers**, notably NHL, leukemia, and MM[1][2][3].